Suppr超能文献

钙通道阻滞剂硝苯地平、维拉帕米、氟桂利嗪以及钙调蛋白拮抗剂三氟拉嗪长期治疗对大鼠大脑皮质β-肾上腺素能受体的影响。

Influence of long-term treatment with the Ca2(+)-antagonists nifedipine, verapamil, flunarizine and with the calmodulin antagonist trifluoperazine on beta-adrenoceptors in rat cerebral cortex.

作者信息

Staneva-Stoytcheva D, Popova J, Mutafova-Yambolieva V, Alov P

机构信息

Institute of Physiology, Bulgarian Academy of Sciences, Sofia.

出版信息

Gen Pharmacol. 1990;21(1):149-52. doi: 10.1016/0306-3623(90)90611-o.

Abstract
  1. The binding of [3H] dihydroalprenolol ((3H]DHA) to beta-adrenoceptors in cerebral cortex membranes (fraction P2) was studied after 13-day oral treatment of male Wistar rats with the Ca2(+)-antagonists nifedipine (20 mg/kg), verapamil (50 mg/kg), flunarizine (10 mg/kg) and with the calmodulin (CaM)-antagonist trifluoperazine (TFP) (3 mg/kg). 2. A significant reduction in the number (Bmax) of binding sites for [3H]DHA was established after the 3 Ca2(+)-antagonists as well as after TFP. 3. No changes in the affinity values (Kd) [3H]DHA binding were found in all treated groups. 4. The fluidity characteristics of the cerebral cortex membranes in nifedipine- and flunarizine-treated rats did not differ from those in controls. 5. Based on these results, we concluded that long-term treatment with Ca2(+)- and calmodulin-antagonists might induce changes in the central adrenergic mechanisms.
摘要
  1. 在用钙拮抗剂硝苯地平(20毫克/千克)、维拉帕米(50毫克/千克)、氟桂利嗪(10毫克/千克)以及钙调蛋白(CaM)拮抗剂三氟拉嗪(TFP)(3毫克/千克)对雄性Wistar大鼠进行13天口服治疗后,研究了[3H]二氢烯丙洛尔([3H]DHA)与大脑皮质膜(P2部分)中β - 肾上腺素能受体的结合情况。2. 在使用三种钙拮抗剂以及TFP后,[3H]DHA结合位点的数量(Bmax)显著减少。3. 在所有治疗组中,未发现[3H]DHA结合的亲和力值(Kd)有变化。4. 硝苯地平和氟桂利嗪治疗的大鼠大脑皮质膜的流动性特征与对照组无异。5. 根据这些结果,我们得出结论,长期使用钙和钙调蛋白拮抗剂可能会引起中枢肾上腺素能机制的变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验